Outlook Therapeutics - OTLK Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.33
  • Forecasted Upside: 441.31%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.17
▲ +0.03 (2.63%)

This chart shows the closing price for OTLK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Outlook Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OTLK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OTLK

Analyst Price Target is $6.33
▲ +441.31% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Outlook Therapeutics in the last 3 months. The average price target is $6.33, with a high forecast of $7.00 and a low forecast of $5.00. The average price target represents a 441.31% upside from the last price of $1.17.

This chart shows the closing price for OTLK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Outlook Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/1/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/6/2023HC WainwrightLower TargetBuy$6.00 ➝ $5.00Low
10/31/2022BTIG ResearchInitiated CoverageBuy$7.00Low
10/3/2022Brookline Capital ManagementReiterated RatingBuyLow
9/13/2022Chardan CapitalInitiated CoverageBuyLow
8/22/2022Ascendiant Capital MarketsLower Target$7.00Low
12/23/2021HC WainwrightReiterated RatingBuy$6.00Low
8/3/2021HC WainwrightBoost TargetBuy$5.00 ➝ $6.00High
2/17/2021LADENBURG THALM/SH SHReiterated RatingBuy$6.00Low
8/27/2020HC WainwrightLower TargetBuy$7.00 ➝ $5.00High
8/18/2020OppenheimerLower TargetOutperform$9.00 ➝ $8.00Low
6/4/2020LADENBURG THALM/SH SHReiterated RatingBuy$6.00Medium
6/3/2020OppenheimerInitiated CoverageBuy$9.00Medium
5/27/2020HC WainwrightLower TargetBuy$8.00 ➝ $7.00High
5/18/2020HC WainwrightReiterated RatingBuy$8.00Medium
5/18/2020OppenheimerReiterated RatingBuyHigh
5/5/2020Brookline Capital ManagementInitiated CoverageBuyHigh
4/14/2020HC WainwrightReiterated RatingBuyHigh
9/11/2019LADENBURG THALM/SH SHInitiated CoverageBuy$9.00High
7/18/2019HC WainwrightInitiated CoverageBuy$8.00High
5/16/2019CIBCInitiated CoverageOutperform ➝ Outperform$12.00High
5/16/2019OppenheimerInitiated CoverageOutperform$12.00 ➝ $12.00High
4/22/2019Ascendiant Capital MarketsInitiated CoverageBuy ➝ Buy$4.00High
(Data available from 1/28/2018 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/2/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/1/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/31/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/30/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/29/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/29/2022
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/28/2023

Current Sentiment

  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Outlook Therapeutics logo
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Read More

Today's Range

Now: $1.17
Low: $1.11
High: $1.17

50 Day Range

MA: $1.06
Low: $0.87
High: $1.35

52 Week Range

Now: $1.17
Low: $0.68
High: $2.12

Volume

469,390 shs

Average Volume

528,699 shs

Market Capitalization

$300.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Outlook Therapeutics?

The following equities research analysts have issued stock ratings on Outlook Therapeutics in the last twelve months: Ascendiant Capital Markets, Brookline Capital Management, BTIG Research, Chardan Capital, and HC Wainwright.
View the latest analyst ratings for OTLK.

What is the current price target for Outlook Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Outlook Therapeutics in the last year. Their average twelve-month price target is $6.33, suggesting a possible upside of 441.3%. Ascendiant Capital Markets has the highest price target set, predicting OTLK will reach $7.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for Outlook Therapeutics in the next year.
View the latest price targets for OTLK.

What is the current consensus analyst rating for Outlook Therapeutics?

Outlook Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OTLK will outperform the market and that investors should add to their positions of Outlook Therapeutics.
View the latest ratings for OTLK.

What other companies compete with Outlook Therapeutics?

How do I contact Outlook Therapeutics' investor relations team?

Outlook Therapeutics' physical mailing address is 4260 U.S. ROUTE 1, MONMOUTH JUNCTION NJ, 08852. The company's listed phone number is (609) 619-3990 and its investor relations email address is [email protected] The official website for Outlook Therapeutics is www.outlooktherapeutics.com. Learn More about contacing Outlook Therapeutics investor relations.